兔抗IDH3B多克隆抗體

Background:

Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which utilizes NAD(+) as the electron acceptor and the other NADP(+). Five isocitrate dehydrogenases have been reported: three NAD(+)-dependent isocitrate dehydrogenases, which localize to the mitochondrial matrix, and two NADP(+)-dependent isocitrate dehydrogenases, one of which is mitochondrial and the other predominantly cytosolic. NAD(+)-dependent isocitrate dehydrogenases catalyze the allosterically regulated rate-limiting step of the tricarboxylic acid cycle. Each isozyme is a heterotetramer that is composed of two alpha subunits, one beta subunit, and one gamma subunit. The protein encoded by this gene is the beta subunit of one isozyme of NAD(+)-dependent isocitrate dehydrogenase. Three alternatively spliced transcript variants encoding different isoforms have been described for this gene.

Applications:

ELISA, WB, IHC

Name of antibody:

IDH3B

Immunogen:

Fusion protein of human IDH3B

Full name:

isocitrate dehydrogenase 3 (NAD+) beta

Synonyms：

RP46; H-IDHB

SwissProt:

O43837

ELISA Recommended dilution:

1000-2000

IHC positive control:

Human thyroid cancer

IHC Recommend dilution:

25-100

WB Predicted band size:

42 kDa

WB Positive control:

HepG2 cells and mouse kidney tissue, lovo cells and mouse eyes tissue, hela cells

WB Recommended dilution:

200-1000